J&J, Legend plan to double Carvykti production Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 12 March, 2025

The CGT race has slowed its roll — but the therapeutic value remains real. What’s next on the horizon? Find out — register today.

presented by Obe­si­ty drug de­vel­op­ment—still room to grow

news Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B Ono licenses rare blood disease drug from Ionis for $280M upfront Legend to double Carvykti production as it targets blockbuster status

Senior Consultant (Clinical or Commercial) IDEA Pharma Remote Vice President, Biology & Translational Research Gondolabio Palo Alto, CA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Mar 12 11:00am ET Building better biologics: Overcoming hurdles in protein therapy manufacturing sponsored by Catalent Mar 18 10:30am ET Fueling Teva Pharmaceuticals’ spectrum of innovation: Behind the Pivot to Growth strategy sponsored by Teva Pharmaceuticals Mar 25 11:00am ET Fireside chat with Lonza CEO Wolfgang Wienand sponsored by Lonza Mar 27 1:00pm ET Unlocking Insights: Leveraging genomic data to understand rare kidney disease sponsored by Natera Apr 02 11:00am ET Future-proofing gene therapy assays: Validation strategies for long-term success sponsored by Precision for Medicine

Join us for an in-depth look at the science shaping biotech’s next breakthroughs. Which pathways, targets and technologies have the potential to steer the next big move in the industry? Register today.

endpoints pharma Corrected: Merck opens billion-dollar US facility to make Gardasil •  Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’ FDA’s medical review departments remain untouched (for now) by Musk’s cuts Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

in case you missed it 1. Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer 2. Bristol Myers buys out cell therapy partner 2seventy bio 3.